Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-08-28
2007-08-28
Priebe, Scott D. (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S320100, C435S069100
Reexamination Certificate
active
10911957
ABSTRACT:
The invention provides an adenoviral vector comprising (a) at least a portion of an adenoviral genome comprising a major late transcription unit containing a terminal exon, wherein the terminal exon comprises a 5′ splice acceptor DNA sequence element and a 3′ polyadenylation signal sequence, and (b) a non-native nucleic acid sequence encoding a protein that does not contribute to the adenoviral vector entry into a host cell, wherein the non-native nucleic acid sequence is positioned within the terminal exon, such that the non-native nucleic acid sequence is selectively expressed in cells within which the adenoviral vector can replicate. The invention further provides an adenoviral vector composition and a method for treating or preventing a pathologic state in a mammal, comprising administering to the mammal the adenoviral vector composition of the invention in an amount sufficient to treat or prevent the pathologic state in the mammal.
REFERENCES:
patent: 5543328 (1996-08-01), McClelland et al.
patent: 5677178 (1997-10-01), McCormick
patent: 6020172 (2000-02-01), Both
patent: 6127525 (2000-10-01), Crystal et al.
patent: 2003/0108524 (2003-06-01), Diagana et al.
patent: 2005/0175589 (2005-08-01), Iggo et al.
patent: 2005/0260162 (2005-11-01), Fueyo et al.
patent: WO99/55365 (1999-11-01), None
Johnson et al, Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents, Cancer Cell, May 2002, vol. 1, pp. 325-337.
Hawkings et al, Gene Delivery from the E3 region of replicating human adenovirus; evaluation of the 6.7 K/gp 19 K region, Gene Therapy, 2001, vol. 8, pp. 1123-1131.
Berk et al.,Ann. Rev. Genet., 20, 45-79 (1986).
Nevins et al.,Adv. Virus Res., 26 1-35 (1981).
Prescott et al.,Mol. Cell. Biol., 17 (4), 2207-2216 (1997).
Falck-Pedersen Erik S.
Gall Jason G. D.
Cornell Research Foundation Inc.
Leydig , Voit & Mayer, Ltd.
Marvich Maria
Priebe Scott D.
LandOfFree
Adenoviral vector with replication-dependent transgene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenoviral vector with replication-dependent transgene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenoviral vector with replication-dependent transgene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861843